Literature DB >> 9056415

TGF-beta signaling in murine embryonic palate cells involves phosphorylation of the CREB transcription factor.

M B Potchinsky1, W M Weston, M R Lloyd, R M Greene.   

Abstract

A number of studies over the last several years have demonstrated a crucial role for TGF-beta in epithelial and mesenchymal differentiation during development of the embryonic palate. Molecular mechanism(s) of signal transduction responsible for eliciting these responses remain unresolved. Since cAMP signaling also modulates the same tissue differentiation in the developing palate and palate-derived cells, we hypothesized that TGF-beta activity may be mediated through cAMP-inducible pathways. We thus examined the effects of TGF-beta on activation of the cAMP regulatory element binding protein CREB, a nuclear transcription factor which mediates transcription of genes containing CRE recognition sequences in their promoters. We examined the ability of TGF-beta-treated murine embryonic palate mesenchymal (MEPM) cells to phosphorylate CREB on the amino acid residue serine 133, phosphorylation of which is indispensable for transcriptional activation. TGF-beta treatment led to increased phosphorylation of CREB ser-133 in a time- and dose-dependent manner. Inhibition of serine-threonine phosphatases by okadaic acid enhanced but did not prolong this response. TGF-beta failed to induce the activity of protein kinase A (PKA), a known CREB kinase. Inhibition of either PKA or calcium/calmodulin kinase II (CaMK II) did not abrogate phosphorylation of CREB by TGF-beta. TGF-beta treatment also did not induce phosphorylation of mitogen-activated protein kinases, erk-1 and erk-2, on tyrosine 185, suggesting that these kinases do not mediate CREB phosphorylation by TGF-beta. Additionally, TGF-beta had no effect on CREB binding to known CREB DNA consensus recognition sequences, CRE and TRE. Together, these data suggest an alternative or novel CREB kinase in MEPM cells through which TGF-beta acts to induce CREB ser-133 phosphorylation and subsequent activation of CRE-containing genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056415     DOI: 10.1006/excr.1996.3422

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Neural crest-specific loss of Prkar1a causes perinatal lethality resulting from defects in intramembranous ossification.

Authors:  Georgette N Jones; Daphne R Pringle; Zhirong Yin; Michelle M Carlton; Kimerly A Powell; Michael B Weinstein; Ramiro E Toribio; Krista M D La Perle; Lawrence S Kirschner
Journal:  Mol Endocrinol       Date:  2010-06-09

2.  Cross-talk between signaling pathways in murine embryonic palate cells: effect of TGF beta and cAMP on EGF-induced DNA synthesis.

Authors:  W M Weston; M B Potchinsky; C M Lafferty; L Ma; R M Greene
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-01       Impact factor: 2.416

3.  Expression profiling of transforming growth factor beta superfamily genes in developing orofacial tissue.

Authors:  Partha Mukhopadhyay; Robert M Greene; M Michele Pisano
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-07

4.  TGF-β1 stimulates mouse macrophages to express APRIL through Smad and p38MAPK/CREB pathways.

Authors:  Young-Saeng Jang; Jae-Hee Kim; Goo-Young Seo; Pyeung-Hyeun Kim
Journal:  Mol Cells       Date:  2011-06-23       Impact factor: 5.034

5.  A novel transcriptional factor with Ser/Thr kinase activity involved in the transforming growth factor (TGF)-beta signalling pathway.

Authors:  S Ohta; M Takeuchi; M Deguchi; T Tsuji; Y Gahara; K Nagata
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

6.  Transforming growth factor-beta1 causes pulmonary microvascular endothelial cell apoptosis via ALK5.

Authors:  Qing Lu; Bhuvic Patel; Elizabeth O Harrington; Sharon Rounds
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-03-06       Impact factor: 5.464

7.  Protein Kinase A Inhibitor H89 Attenuates Experimental Proliferative Vitreoretinopathy.

Authors:  Yali Lyu; Wei Xu; Jieping Zhang; Mengwen Li; Qingyi Xiang; Yao Li; Tianhao Tan; Qingjian Ou; Jingfa Zhang; Haibin Tian; Jing-Ying Xu; Caixia Jin; Furong Gao; Juan Wang; Weiye Li; Ao Rong; Lixia Lu; Guo-Tong Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.